University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the ...

WASHINGTON - The University of Kentucky is set to begin a Phase IIb clinical trial evaluating a novel treatment for vivax malaria, combining drug candidate SJ733 with the previously approved ...

WASHINGTON - The University of Kentucky is set to begin a Phase IIb clinical trial evaluating a novel treatment for vivax malaria, combining drug candidate SJ733 with the previously approved ...

TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, ...

SciSparc has signed a clinical trial agreement with Yale University to add the Yale Child Study Center as a site for conducting the Phase IIb trial of SCI-110 to treat Tourette Syndrome (TS) patients.

Siemens is a German multinational manufacturer founded in 1847. Siemens Motion Control, based in Congleton, manufactures variable speed drives used to control electric motors. Industry 4.0 has been a ...